Financial Health Snapshot
What does Waters Corporation’s latest financial snapshot show?
Strong overall, with recurring revenue and cash conversion as the strongest factor. The main concern is leverage after the acquisition.
For December 31, 2025, this snapshot blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. It fits Waters Corporation’s broader business profile, including its operating model and history in Waters Corporation (WAT): History, Ownership, Mission, How It Works & Makes Money.
Revenue growth deserves deeper analysis first because it anchors the recurring-revenue story and helps explain whether the margin and cash-flow profile can support the current debt load.
Revenue and earnings quality
Does Waters Corporation’s revenue growth translate into quality earnings?
Mixed. Revenue growth is strong, but the clearest divergence is that GAAP operating income, net income, and diluted EPS were pressured even as revenue and non-GAAP EPS improved, so the quality case depends on whether recurring, regulated demand keeps converting into profit.
Revenue growth shows the size of the top-line move, but quality depends on whether that growth shows up in operating income, net income, and EPS across comparable periods. Investors compare those figures to see if volume and recurring demand are producing durable margins, or if earnings are being held back by costs, mix, or other charges.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $3165B for full-year 2025, up 70% as reported and in constant currency | Prior full-year revenue was not supplied | Organic and constant-currency growth, with recurring revenue and service and chemistry strength | The growth source looks repeatable if regulated pharma and recurring consumables stay strong |
| Operating Income | Latest verified direction was -11513% | Previous comparable value was not supplied | Operating income moved differently from revenue | Top-line growth did not yet flow cleanly into operating profit |
| Net Income | Latest verified direction was -13197% | Previous comparable value was not supplied | Verified GAAP pressure outweighed revenue growth | Final earnings did not confirm the sales surge |
| Diluted EPS | Latest verified diluted EPS growth was -12308% | Previous comparable diluted EPS was not supplied | Per-share results were weaker than revenue | Shareholders did not receive the same growth the business reported |
How durable is Waters Corporation’s revenue?
Fairly durable. The strongest signal is recurring revenue, which typically exceeds 700% of annual revenue and rose 80% in constant currency in 2025. The biggest limitation is concentration in regulated pharma and China, which improves visibility but adds policy and cyclicality risk.
- Demand Quality: Recurring service and chemistry demand supports visibility, especially in pharma QA/QC, clinical, and diagnostics.
- Pricing and Volume: Q1 2026 organic revenue grew 130% as reported, driven by high-single-digit instrument growth; the full price-volume split was not supplied.
- Diversification: Exposure is tied to regulated pharma and China pharma sales, which helps predictability but leaves concentration risk.
That mix makes profitability and cash conversion the next test.
Profitability and Cash
Is Waters Corporation’s profit supported by cash flow after the merger?
Adjusted operating profitability is expected to improve, with 2026 Adjusted Operating Margin at approximately 281%, or 100 basis points above the initial deal model. Cash support is less clear right now because the latest supplied operating cash flow and free cash flow growth figures are sharply negative, so reported earnings are not yet fully confirmed by cash conversion.
For analysis, keep profit and cash separate: gross, operating, and net margins show pricing, mix, cost control, and financing effects, while net income can also reflect interest, taxes, and non-cash amortization. Waters Corporation’s merger case points to operating leverage from pricing, recurring service and chemistry mix, and SG&A discipline, but integration-period cash flow still needs confirmation.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Unavailable in supplied data. | Unavailable in supplied data. | Pricing, mix, volume, and input-cost evidence were not supplied. | Product economics cannot be verified from the provided figures alone. |
| Operating Margin | Approximately 281% in 2026 Adjusted Operating Margin. | Initial deal model; exact margin not supplied. | Expected 100 basis points of expansion versus the initial deal model, helped by pricing, recurring service and chemistry mix, and SG&A discipline. | Scale appears to be improving operating efficiency in the merger model. |
| Net Margin | Unavailable in supplied data. | Unavailable in supplied data. | Interest expense, other expenses, taxes, and non-cash amortization were supplied, but a verified margin was not. | Final profitability cannot be confirmed from the provided data alone. |
| Operating Cash Flow | Operating Cash Flow Growth: -10182% in the latest FMP growth data. | Previous compatible value not supplied. | Latest growth data points to weak conversion during integration. | Accounting earnings are not yet clearly converting into operating cash. |
| Free Cash Flow | Free Cash Flow Growth: -13344% in the latest FMP growth data. | Previous supplied value not available. | Capital-spending details were not supplied, but conversion is said to typically exceed 200% of revenue. | Reinvestment and financing capacity need closer monitoring until cash normalizes. |
What most affects Waters Corporation’s cash conversion after the merger?
The biggest verified issue is integration-period cash flow weakness, while non-cash amortization, interest expense, and SG&A discipline also matter. The supplied data does not establish whether this is temporary or structural.
- Main Driver: Integration-period cash conversion looks temporary so far, but the supplied data does not prove how long the pressure will last.
- Evidence Gap: No verified capital expenditure figure, working-capital detail, or actual cash flow level was supplied.
- Metric to Monitor: Follow operating cash flow conversion and free cash flow conversion in the next reporting period.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For more detail on strategy context, see Mission Statement, Vision, & Core Values (2026) of Waters Corporation (WAT).
Funding Capacity
Can Waters Corporation manage debt and liquidity after the BD merger?
Waters Corporation is Mixed. Liquidity is supported by cash and current assets, but the main concern is the new debt load and whether post-merger cash conversion is strong enough to fund debt service and deleveraging.
Cash matters, but it does not tell the full story. For Waters Corporation, the balance sheet needs to be read alongside working capital, asset quality, debt service, solvency, liquidity, and refinancing access, especially after the new financing tied to the BD merger.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash And Cash Equivalents: $46200M; Cash And Short Term Investments: $46200M; Net Receivables: $175B; Inventory: $150B; Other Current Assets: $35300M; Total Current Assets: $406B | Mixed | Near-term obligations appear covered, but investors still need to watch whether working capital stays efficient during integration. |
| Total and Net Debt | Total Debt: $557B; Cash And Cash Equivalents: $46200M | Mixed | Leverage is meaningful, so flexibility is more constrained than before the merger-related financing. |
| Debt Service and Refinancing | Waters Corporation entered a Term Loan Credit Agreement for $40B in unsecured loans to finance the cash distribution to BD; debt growth: 27355% | Mixed | Debt service depends on integration execution and cash generation, not just existing liquidity. |
| Asset Quality | Receivables Growth: 11150%; Inventory Growth: 16137%; Asset Growth: 38322% | Mixed | The larger asset base can support the business, but faster growth in receivables and inventory raises execution and collection risk. |
| Liabilities and Equity | Latest verified total liabilities and shareholders' equity were not supplied in the prompt. | Mixed | The capital base cannot be fully judged from the supplied data, so investors should focus on leverage trends and cash generation. |
Which balance-sheet risk matters most for Waters Corporation after the BD merger?
The biggest risk is refinancing and deleveraging pressure, because the new borrowing and larger balance sheet make future cash conversion the key test.
- Current Exposure: Total Debt: $557B against Cash And Cash Equivalents: $46200M, with $406B in Total Current Assets.
- Protection: Cash, short-term investments, and the larger current-asset base give Waters Corporation near-term liquidity support.
- Warning Signal: Watch whether receivables, inventory, and debt all keep rising faster than operating cash flow after the merger.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For a related investor-angle view, Exploring Waters Corporation (WAT) Investor Profile: Who's Buying and Why? can help connect balance-sheet risk with market sentiment and ownership behavior.
Capital Efficiency
Can Waters Corporation protect returns while reinvesting in growth?
Capital efficiency is Mixed, and internal cash appears sufficient for reinvestment needs only if post-merger margins and synergy gains hold. Waters Corporation’s cash generation looks strong, but the enlarged capital base and equity dilution after the BD transaction still need proof.
Return measures should be read alongside leverage, asset intensity, capital expenditure, working capital, and outside funding needs. Waters Corporation’s reinvestment profile matters because heavy R&D, post-merger integration, and debt reduction can all pressure near-term returns even when cash flow looks healthy. The broader company background also matters, so Mission Statement, Vision, & Core Values (2026) of Waters Corporation (WAT) helps frame the strategy behind the capital plan.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Latest ROIC was not supplied; the issue is whether the enlarged invested capital base earns enough incremental profit after the BD assets. | ROIC looks better only if operating margins and capital efficiency improve after integration. | Shows whether invested capital is creating operating value or being diluted by a larger asset base. |
| ROE and ROA | ROE is affected by leverage, equity changes, and dilution after Waters issued 3854M shares of common stock to BD shareholders; ROA is pressured by latest FMP asset growth of 38322%. | ROE can look weaker if equity expands faster than earnings; ROA weakens when assets rise faster than profit. | Explains shareholder return quality and asset efficiency without treating leverage as automatic strength. |
| Maintenance and Growth Investment | Latest FMP shows Research And Development Expenses of $9600M, R&D Intensity of 60%–70% of revenue, and Growth Capital Expenditure of -007% for 2026-04-04. | R&D points to continued growth investment, while capex discipline suggests limited physical expansion burden. | Signals that much of the capital need is tied to innovation and integration rather than heavy plant spending. |
| Internal Funding Capacity | Free Cash Flow Conversion typically exceeds 200% of revenue, but reinvestment must also cover R&D, working capital, and debt reduction. | Funding looks internally supported, but only if cash flow stays strong enough after merger-related demands. | Suggests investment is partly internally funded, with leverage and flexibility depending on sustained cash conversion. |
Are Waters Corporation’s returns on capital sustainable?
The strongest durability source is cash generation, but sustainability depends on synergy realization and post-merger margin recovery. If integration costs, working-capital needs, or debt reduction absorb cash, returns can weaken fast.
- Operating Source: R&D intensity and cash conversion support returns if post-merger margins improve.
- Funding Requirement: The largest verified need is continued R&D plus working capital and debt reduction.
- Durability Test: Watch whether FCF conversion falls or margins fail to expand after integration.
Financial Resilience
How resilient is Waters Corporation, and which warning signs matter most?
Mixed. The main buffer is recurring revenue that is typically above 700% of annual revenue, plus high-volume regulated demand and raised 2026 revenue guidance. The most important verified warning sign is slower reported revenue versus constant-currency performance, especially if currency pressure keeps widening net income volatility.
Waters Corporation has decent resilience because its business mix supports repeat demand and its expected adjusted operating margin expansion should help cash generation. Still, resilience is not the same as immunity. If you are also looking at ownership behavior, Exploring Waters Corporation (WAT) Investor Profile: Who's Buying and Why? adds useful context on how investors may be reading the risk profile.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Foreign currency translation effects and increases in foreign net operating losses can make reported revenue and net income more volatile, which can also weaken operating leverage and debt capacity if growth slows. | Recurring revenue, high-volume regulated applications, and raised 2026 revenue guidance support steadier demand and margin improvement. | Watch for slower organic revenue growth, a wider gap between reported and constant-currency revenue, and weaker margin expansion. |
| Working-Capital or Investment Pressure | China demand swings and supply chain disruption can absorb cash through inventory, receivables, and order timing, while expansion needs can reduce free cash flow conversion. | Internal funding capacity is supported by recurring demand and regulated end markets that usually produce repeatable cash flow. | Monitor weaker free cash flow conversion and any rise in working capital tied to slower operating cash flow. |
| Interest or Refinancing Pressure | Higher interest burden would reduce free cash flow and limit flexibility if operating income weakens. | Margin expansion and recurring revenue should help protect coverage if conditions stay stable. | Watch for rising interest expense relative to operating income, tighter coverage, or signs that financing conditions are worsening. |
Which financial warning signs should investors monitor at Waters Corporation?
The top signals are slower organic revenue growth, weaker free cash flow conversion, and a rising interest burden relative to operating income. Currency-driven volatility is already a confirmed pressure, while China weakness and tariff exposure are future risks if instrument orders soften.
Currency and tax volatility
Foreign currency translation effects and higher foreign net operating losses can swing reported earnings even when constant-currency demand holds up. The key check is reported revenue versus constant-currency revenue, plus tax effects on net income.
China order swings
China Pharma Sales grew over 500% in Q1 2026 after prior supply chain challenges, but the market still looks sensitive to macro slowdown and potential tariff impacts on instrument orders. Track China sales growth and order momentum.
Integration execution risk
Merging the $175B BD Biosciences deal value context assets into a roughly $30B scale organization can strain culture, systems, and supply chain execution. The next metric to watch is whether margin expansion and cash flow stay on plan.
Financial Health Scorecard
What does Waters Corporation’s financial health mean for investors?
Waters Corporation’s scorecard is Mixed, with the strongest factor being revenue growth and cash generation, and the weakest factor being leverage and integration risk. The most important condition for the investment case is whether debt comes down while operating performance stays clean.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | Full-year revenue of $3165B grew 70% in 2025, Q1 2026 revenue of $1267B beat guidance, and full-year 2026 guidance rose to $641B–$646B. |
| Profitability and Cash | Strong | 2026 adjusted operating margin is expected near 281%, and free cash flow conversion typically exceeds 200% of revenue, though GAAP pressure still needs watching. |
| Balance Sheet and Liquidity | Mixed | Add total debt of $557B and the $40B unsecured term loan make deleveraging important, even with an established operating base. |
| Capital Efficiency | Mixed | R&D intensity of 60%–70% supports growth, but dilution and a larger asset base can pressure returns and slow capital efficiency gains. |
| Financial Resilience | Mixed | Recurring regulated demand helps, but FX, China, and integration risk remain material pressure points if execution weakens. |
- What Supports the Thesis: Revenue growth plus strong cash conversion create a solid operating buffer, which matters for funding flexibility and debt paydown.
- What Challenges the Thesis: Leverage and integration risk are the main uncertainties, especially if growth slows or cash gets tied up.
- What to Monitor: Organic revenue growth, free cash flow conversion, and $557B total debt.
That mix should feed directly into forecasts, scenario analysis, and valuation assumptions, especially around margin durability, deleveraging speed, and downside resilience.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How much cash supports Waters deleveraging?
Waters had Cash And Cash Equivalents: $46200M on 2026-04-04 and Free Cash Flow Conversion typically exceeds 200% of revenue The deleveraging case depends more on sustained operating cash flow after integration than on cash alone
Is Waters debt manageable after the BD merger?
Debt appears manageable but not low risk Waters added a $40B unsecured term loan, and latest enterprise value data shows Add Total Debt: $557B on 2026-04-04 Investors should track free cash flow conversion and debt reduction
What does Waters recurring revenue mix imply?
Recurring revenue typically exceeds 700% of annual revenue, supported by service and chemistry demand That mix can improve visibility, cash generation, and resilience, especially in regulated Pharma QA/QC, clinical, and diagnostics applications
Can Waters maintain returns while integrating SpinCo?
Returns are not proven yet because ROIC, ROE, and ROA were not supplied The key test is whether R&D Intensity: 60%–70%, synergy execution, cash conversion, and deleveraging can offset dilution and the larger asset base
Which warning signs matter most for resilience?
Watch organic revenue growth, free cash flow conversion, and Add Total Debt FX translation, China volatility, and integration execution are the main pressure points because they can affect reported growth, margins, cash generation, and deleveraging capacity